Ignite Creation Date:
2024-05-06 @ 12:16 PM
Last Modification Date:
2024-10-26 @ 12:56 PM
Study NCT ID:
NCT03719898
Status:
WITHDRAWN
Last Update Posted:
2021-01-05
First Post:
2018-10-16
Brief Title:
Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Organization Data
Organization:
Fox Chase Cancer Center
Class:
OTHER
Study ID:
HM-117
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fox Chase Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None